Skip to main content
TipRanks
Go Ultimate75% OFF

IQVIA Holdings (IQV) AI Stock Analysis

1,106 Followers
IQV

IQVIA Holdings

(NYSE:IQV)

Select Model
Rating:74Outperform
Price Target:$306.00▲(18.79% Upside)
Action:reiterated
Date:10/27/26

The score is driven primarily by solid fundamentals (steady growth and strong cash generation) and a very positive earnings update with raised FY2026 guidance and strong bookings momentum. Technicals also support the view with price above key moving averages and positive MACD. The main constraints are leverage (financial risk) and a relatively high P/E multiple, with refinancing activity a modest supportive factor.

Positive Factors
Steady Growth and ProfitabilityIQVIA has expanded revenue while sustaining healthy operating and net margins, indicating a resilient service model and effective cost control. This combination supports recurring investment in technology and delivery capabilities, giving the company a durable base for continued growth across the product lifecycle.
Negative Factors
Elevated LeverageHigh leverage reduces financial flexibility and leaves earnings and cash flow more exposed to refinancing conditions and interest costs. Although IQVIA generates substantial cash, debt service and maturity management can constrain acquisitions, technology investment, and the company’s ability to absorb weaker demand.

IQVIA Holdings Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.

$0.00$1.00B$2.00B$3.00B$4.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Revenue growth is broadening beyond the Americas: Europe and APAC are the faster-growing regions (APAC showing the steepest recent pickup), turning IQVIA into a more diversified geographic growth story. Management’s raised guidance, accelerating organic growth and strong R&DS bookings/backlog validate that momentum, but expect limited margin leverage near term—FX headwinds, pass‑through revenue and lower‑margin acquisition mix will likely mute profit expansion even as top‑line trajectory improves.

Data provided by:The Fly

IQVIA Holdings (IQV) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%IQV+18.65%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$42.45B
Dividend Yield
―
Average Volume (3M)
1.46M
Price to Earnings (P/E)
31.1
Beta (1Y)
0.80
Revenue Growth
8.88%
EPS Growth
13.11%
Country
US
Employees
94,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-P...

How the Company Makes Money

IQVIA primarily makes money by selling services and technology solutions to life sciences customers under contracts that span research and development through commercialization. A major revenue stream is its CRO/clinical development business, where I...

IQVIA Holdings Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:-5.85%|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was strongly positive. IQVIA reported revenue, adjusted EBITDA, and adjusted EPS above guidance; accelerating organic growth across clinical and commercial solutions; record four-year clinical bookings; improving win rates; strong demand indicators; expanding AI adoption; strong free cash flow; and raised full-year guidance. The principal challenges were the $2.1 billion inactive-trial backlog adjustment, pass-through and foreign-exchange headwinds, difficult fourth-quarter comparisons, leverage, and historical market uncertainty, but management explicitly stated that the backlog adjustment did not affect financial results or guidance and emphasized continued operational momentum.

Positive Updates

Revenue Exceeded Guidance with Accelerating Organic Growth
Third-quarter revenue was $4.43 billion, up 8% on a reported basis and 8.6% at constant currency. Organic revenue growth was approximately 6%, more than 2x the rate delivered a year ago. Revenue exceeded the high end of guidance.

Negative Updates

Backlog Adjustment for Inactive Trials
A detailed review of inactive trials resulted in an approximately $2.1 billion adjustment to backlog. The trials had generally been inactive for more than 18 months and, in coordination with customers, there was no reason to assume the work would resume in the near term. Management stated that this adjustment had no impact on historical financial results, 2026 guidance, net new bookings, or next-12-month revenue from backlog.

Company Guidance

Management raised full year 2026 guidance, expecting revenue to be between 17.350 billion and $17.5 billion, representing year over year growth of 6.4% to 7.3%, with >1 point constant currency or revenue growth acceleration versus prior year, approximately 200 to 250 basis points of contribution from acquisitions, and approximately 20 basis points of tailwind from foreign exchange; adjusted EBITDA is expected to be between 4.025 billion and $4.055 billion, growing 6.3 to 7% year over year with flat margins year over year at approximately 23.2%; adjusted diluted EPS is expected to be between $12.90 and $13, up 8.2 to 9.1% versus prior year or 8.6% at the midpoint; fourth-quarter run rate assumptions include net interest expense around $210 million, just over $160 million in depreciation and amortization, and a weighted average diluted share count of approximately 169 million shares, with foreign currency rates as of October 26th continuing for the balance.

IQVIA Holdings Financial Statement Overview

Summary

Solid operating profile with steady revenue expansion, durable profitability, and strong free cash flow generation. The key offset is a leveraged balance sheet (elevated debt vs. equity and higher sensitivity to rates/refinancing), which limits the overall financial quality despite strong cash generation.

Income Statement

78Positive

Balance Sheet

56Neutral

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue17.31B16.31B15.40B14.98B14.41B13.87B
Gross Profit4.58B5.43B5.38B5.24B5.03B4.64B
EBITDA3.60B2.94B3.45B3.26B2.91B2.77B
Net Income1.39B1.36B1.37B1.36B1.09B966.00M
Balance Sheet
Total Assets30.47B29.94B26.90B26.68B25.34B24.69B
Cash, Cash Equivalents and Short-Term Investments2.42B2.14B1.84B1.50B1.31B1.48B
Total Debt16.31B16.17B14.16B13.90B13.01B12.44B
Total Liabilities23.68B23.31B20.83B20.57B19.57B18.65B
Stockholders Equity6.66B6.50B6.07B6.11B5.76B6.04B
Cash Flow
Free Cash Flow2.08B2.05B2.11B1.50B1.59B2.30B
Operating Cash Flow2.74B2.65B2.72B2.15B2.26B2.94B
Investing Cash Flow-2.24B-2.31B-1.44B-1.60B-2.01B-2.10B
Financing Cash Flow-34.00M-150.00M-878.00M-382.00M-329.00M-1.24B

IQVIA Holdings Technical Analysis

Technical Analysis SentimentNeutral
Last Price257.60

Price Trends

50DMA267.32Negative
100DMA249.41Positive
200DMA211.33Positive

Market Momentum

MACD-0.28Positive
RSI40.36Neutral
STOCH21.93Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Neutral. The current price of 257.60 is below the 20-day moving average (MA) of 270.48, below the 50-day MA of 267.32, and above the 200-day MA of 211.33, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 40.36 is Neutral, neither overbought nor oversold. The STOCH value of 21.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IQV.

IQVIA Holdings Risk Analysis

IQVIA Holdings disclosed 51 risk factors in its most recent earnings report. IQVIA Holdings reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Increasing focus on environmental sustainability and social initiatives could increase our costs, and inaction could harm our reputation and adversely impact our financial results.Q4, 2023
2.The biopharmaceutical services industry is highly competitive and our business could be materially impacted if we do not compete effectively or rapidly adapt to technological change.Q4, 2023
3.We may be affected by healthcare reform and potential additional reforms, which may adversely impact the biopharmaceutical industry and reduce demand for our services or negatively impact our profitability.Q4, 2023

IQVIA Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IQV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MEDPMEDP84Outperform$18.27B35.3299.76%―20.35%25.24%
DGXDGX76Outperform$28.20B25.2015.21%1.32%9.13%17.93%
LHLH75Outperform$29.90B30.0911.54%0.78%6.02%19.63%
IQVIQV74Outperform$42.45B31.1121.82%―8.88%13.11%
ICLRICLR71Outperform$14.61B33.264.85%―0.67%43.70%
CRLCRL62Neutral$15.92B326.421.32%―-1.16%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%IQVCRLICLRLHDGXMEDPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IQV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IQVIQVIA Holdings257.6040.1218.45%
CRLCharles River Laboratories Intl332.16170.52105.49%
ICLRIcon Plc195.0236.2122.80%
LHLabcorp Holdings Inc.368.24110.3042.76%
DGXQuest Diagnostics256.3573.4740.17%
MEDPMedpace Holdings Inc653.0960.9110.29%

IQVIA Holdings Corporate Events

Business Operations and StrategyPrivate Placements and Financing

IQVIA Holdings Completes $2 Billion Senior Notes Issuance

Neutral
Sep 23, 2026

On September 23, 2026, IQVIA Inc., a subsidiary of IQVIA Holdings, completed a $2 billion issuance of 6.375% senior notes due March 15, 2034, structured as unsecured obligations with semi-annual interest payments starting March 15, 2027. The notes, i...

Business Operations and StrategyPrivate Placements and Financing

IQVIA Holdings Announces $2 Billion Senior Notes Offering

Positive
Sep 9, 2026

On September 9, 2026, IQVIA Holdings Inc. announced that its wholly owned subsidiary IQVIA Inc. plans to raise $2 billion through a private offering of senior notes due 2034. The notes, bearing interest at 6.375% per annum, are being marketed to qual...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026